Listen on the go
Downloads

View and download resources from this activity to support your learning and share with colleagues

Download Slides
Download Slides
Download Slides
Download Slides
Download Slides
Download Slides
Download Slides
Download Slides
Download Slides
CORRECT!
Next question
Faculty & Disclosures
Prof. Anthony Bewley

Barts Health NHS Trust, London, UK

Professor Anthony Bewley, BA (Hons), FRCP, is a consultant dermatologist at Barts Health NHS Trust, London, UK, and an honorary professor at Queen Mary College (University of London). read more

He is fully trained in general dermatology, with a special interest in psychodermatology (psycho-cutaneous medicine). He is the lead for commercial clinical trials research at the Barts Health Dermatology Department, and has published extensively in international peer-reviewed journals on a range of different areas within dermatology. Prof. Bewley was chair of Psychodermatology UK 2008–2020; president of the UK Dowling Dermatology Club 2019–2020 and honorary treasurer of the British Association of Dermatologists (2019–2022). He is the co-editor of Practical Psychodermatology and Psychodermatology in Clinical Practice. He is president of the European Society for Dermatology and Psychiatry

Prof. Anthony Bewley discloses: Consulting or advisory board fees from AbbVie, Almirall, BMS, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi and UCB; Grants/research support from Janssen.
Prof. Martin Metz

Institute of Allergology (IFA), Charité – Universitätsmedizin Berlin, Germany

Martin Metz, MD, is a professor of dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin, Germany, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Department of Allergology and Immunology. read more

He received his medical education at the Free University of Berlin and the Humboldt University of Berlin. He specialized in dermatology at King’s College Hospital, London, UK, and the University of Mainz, Germany, and in experimental pathology at Beth Israel Deaconess Medical Centre and Harvard Medical School in Boston (1997–1998) and Stanford University (2004–2006) in the USA. He is board certified in dermatology and allergology, and is head of the specialty outpatient clinics for pruritus, head of translational research, and deputy head of clinical research at the Institute of Allergology, Charité – Universitätsmedizin Berlin. His main scientific areas of interest are mast cell biology, neuroimmunology, inflammation and innate immunity, with a major clinical and translational focus on pruritus and mast cell mediated diseases.

Prof. Martin Metz discloses: Speaker, consulting, advisory board or panel fees from Amgen (relationship ended), Celldex Therapeutics (relationship ended), Galderma and Sanofi-Aventis.
Dr Manuel Pereira

Institute of Allergology (IFA), Charité – Universitätsmedizin Berlin, Germany

Manuel P Pereira, MD, PhD, is dermatologist at the Institute of Allergology at the Charité – Universitätsmedizin Berlin, Germany, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Department of Allergology and Immunology. read more

He received his medical education at the University of Porto, Portugal, and at Charité – Universitätsmedizin Berlin. He completed his training in dermatology at the University Hospital Münster, Germany. Additionally, he obtained a PhD from the Neuroscience Graduate School at the University of Copenhagen, Denmark. His main research interests include translational and clinical research in chronic itch, chronic prurigo and atopic dermatitis.

Dr Manuel Pereira discloses: Speaker, consulting, advisory board or panel fees from AbbVie, Beiersdorf, Eli Lilly, GA2LEN, Galderma, Menlo Therapeutics, Novartis, Sanofi, Trevi Therapeutics and Unna Academy.
Ms Sailaja Maganti

Prurigo Nodularis International, London, UK

Ms Sailaja Maganti is the founder of Prurigo Nodularis International (PNI), London, UK. read more

With almost 20 years’ lived experience of prurigo nodularis (PN), Sailaja leads the largest global support group for patients with PN. With almost 5,000 subscribers, she is currently establishing PNI as a formal charity and will assume the roles of chair and trustee.

Having endured a 9-year rollercoaster of a diagnosis journey, prurigo nodularis completely upended her life. This experience led Sailaja to become a passionate and outspoken advocate, determined to see those with a rare disease receive the care and dedicated treatments they all need and deserve, on par with patients of mainstream conditions.

Sailaja is able to leverage a deep and broad skill set gained from a lengthy career in investment and central banking to her advocacy work.

Ms Sailaja Maganti discloses: Consulting fees from Galderma.
touchIMMUNOLOGY touchIMMUNOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Dermatological Conditions

    An Introduction to Dermatological Conditions

    Autoimmunity and deregulation of the immune system contribute to many skin diseases including systemic sclerosis, dermatomyositis, psoriasis, vitiligo, alopecia areata and lichen sclerosus; as well as inflammatory diseases such as hidradenitis suppurativa, allergic contact dermatitis and atopic eczema; and also autoimmune blistering diseases, including pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Established treatments include systemic corticosteroids and immunosuppressive therapies, while new therapies in development include biologic therapies targeting cytokines such as tumour necrosis factor alpha (TNF-alpha) and interleukins IL-23 and IL-17; enzymes such as Janus kinase-1 (JAK-1); and the regulatory proteinretinoic acid receptor-related-orphan-receptor-gamma t (RORγt).

    Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.

    Dermatological Conditions Content

    Dermatological Conditions
    Watch Time: 38 mins
    touchMDT
    Establishing treatment and care pathways for patients with prurigo nodularis: A patient-centric focus from multidisciplinary perspectives
    CE/CME ACCREDITED Dr Manuel Pereira, Ms Sailaja Maganti, Prof. Anthony Bewley, Prof. Martin Metz Translations available:

    Select a discussion in our hub to watch our multidisciplinary experts, including a patient advocate, share important perspectives on the need to establish patient-centric treatment and care pathways for the management of prurigo nodularis.

    Learning objectives
    Learning Objectives
    • Define the burden of disease and unmet need for prurigo nodularis
    • Recall and apply the range of treatment and management options available for prurigo nodularis, including approved treatments, appropriately
    • Implement a holistic, multidisciplinary approach to care for prurigo nodularis, taking into account patient’s individual circumstances and needs
    touchMEETING HIGHLIGHTS
    ADVENT at EADV 2023: Expert insights on AD in children, PN, and CSU
    For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, China, Colombia, Costa Rica, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Guatemala, Hong Kong, Hungary, Iceland, Italy, Kuwait, Lebanon, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Singapore, South Korea, Spain, Sudan, Sweden, Taiwan, Thailand, The Netherlands, and UAE
    View Time: 8 mins Sponsored content

    Watch highlights of three ADVENT symposia presented at EADV 2023

     

    MAT-GLB-2303418 V1.0 12/2023
    Date of Preparation: December 2023
    Paediatric Dermatology, Atopic Dermatitis, Dermatological Conditions, Immunology
    Watch Time: 38 mins
    touchPANEL DISCUSSION
    Paediatric atopic dermatitis: Evolving strategies for improved management
    CE/CME ACCREDITED Dr Elaine Siegfried, Assist. Prof. Nives Pustišek, Prof. Andreas Wollenberg

    Watch three experts discuss how they manage moderate-to-severe atopic dermatitis in children.

    Learning objectives
    Learning Objectives
    • Recognize the burden of atopic dermatitis in children, their families and caregivers and its impact on quality of life, particularly in moderate-to-severe disease
    • Summarize the latest data for systemic treatment options in children and adolescents with moderate-to-severe atopic dermatitis
    • Assess how continuity of care in children and adolescents impacts long-term symptom control
    Dermatological Conditions
    EADV Congress 2023

    We’re looking forward to the upcoming EADV Congress 2023 which is taking place in Berlin between 11-14 October.  Promising its attendees an opportunity to explore the latest technologies, treatments and products in the field of Dermatology & Venereology, we are excited to be there in-person to provide independent, expert video coverage of key data through […]

    Dermatological Conditions
    Watch Time: 49 mins
    touchPANEL DISCUSSION
    Prurigo nodularis: Improving awareness, diagnosis, management and quality of life
    CE/CME ACCREDITED Prof. Sonja Ständer, Dr Shawn Kwatra, Prof. Matthias Augustin Translations available:

    Watch three experts discuss the symptom burden faced by patients with prurigo nodularis, and how clinicians can optimize diagnosis and treatment of the disease. **Now including 2023 UPDATE (scroll to chapter 5)**

    Learning objectives
    Learning Objectives
    • Define the burden of disease and unmet need for prurigo nodularis
    • Identify the differential diagnoses for patients with prurigo nodularis and recall the range of treatment and management options available
    • Evaluate the emerging treatment options for the management of prurigo nodularis and how these may impact current clinical practice
    touchMEETING HIGHLIGHTS
    Latest insights on atopic dermatitis and prurigo nodularis
    For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Lebanon, Macau, Malaysia, The Netherlands, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, and UAE
    View Time: 5 mins Sponsored content

    Key updates from 2 cutting-edge expert symposia presented at WCD 2023

     

    MAT-GLB-2304709 v1 10/2023
    Date of Preparation: October 2023
    Dermatological Conditions
    Developed by Touch
    Claudia De La Cruz, Dermatology Meeting News 2023: Effisayil 1 – a phase 2 study of spesolimab for generalized pustular psoriasis
    Watch Time: 6 mins

    Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]

    Dermatological Conditions
    Dedee Murrell Pemphigus
    Developed by Touch
    Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prevalence, clinical presentations & impact on quality of life
    Watch Time: 9 mins

    Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]

    Dermatological Conditions
    Dedee Murrell Pemphigus
    Developed by Touch
    Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prognosis, current treatment paradigm & pipeline therapies
    Watch Time: 7 mins

    The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72